LAV INVESTMENT ADVISER LIMITED

Thesis

LAV Investment Adviser Limited is a biomedical venture capital firm focused on investing in companies developing breakthrough products for disease treatment and human health improvement. Their investment thesis centers on long-term thinking, people, quality science, and innovative products. The firm's primary sector focus includes biopharmaceuticals, human therapeutics, medical devices, and diagnostics. While generally stage-agnostic, LAV shows a preference for Series B and later rounds, particularly in China-based startups. Their geographic focus is predominantly China, with increasing investment in the United States, especially for companies with a 'China angle.' LAV often acts as a lead investor, offering capital alongside strategic guidance, executive recruitment, industry connections, and business development support. The typical check size ranges from $5 million to $30 million. The firm was founded in 2008, spun off as an independent investment management company in 2011, and is headquartered in Shanghai, China, with offices in Hong Kong and Palo Alto. Associated entity Lilly Asia Ventures has approximately $4.5 billion in AUM, with specific funds like LAV Fund VI ($900M), LAV Fund VI Opportunities ($450M), and LAV Fund VII ($547M reported sold) also noted.

Related lists

• Seed-stage AI investors
• Series B AI investors
• Series C+ AI investors